• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Champions Oncology Inc.

    8/27/24 4:35:29 PM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CSBR alert in real time by email
    DEFA14A 1 noticeandaccesscardfy24pro.htm DEFA14A Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 14A
     
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934

     
    Filed by the Registrant x
    Filed by a Party other than the Registrant o
     
    Check the appropriate box:
    ¨ Preliminary Proxy Statement
    ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ¨ Definitive Proxy Statement
    ý Definitive Additional Materials
    ¨ Soliciting Material Pursuant to Rule 14a-11(c) or Rule 14a-12
    Champions Oncology, Inc.
    (Name of Registrant as Specified in Its Charter)
     
    N/A
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
     
    Payment of Filing Fee (Check the appropriate box): 
    ý No fee required.
    ¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.



     



    (1)Title of each class of securities to which transaction applies:
      
    (2)Aggregate number of securities to which transaction applies:
      
    (3)Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
      
    (4)Proposed maximum aggregate value of transaction:
      
    (5)Total fee paid:
      
    o Fee paid previously with preliminary materials.
     
    o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously.  Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
    (1)Amount Previously Paid:
      
    (2)Form, Schedule or Registration Statement No.:
      
    (3)Filing Party:
      
    (4)Date Filed:
      








    CHAMPIONS ONCOLOGY, INC.CONTROL ID:
    REQUEST ID:
    IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS for the Annual Meeting of Stockholders
    DATE:October 14, 2024
    TIME:9:00 a.m. local time
    LOCATION:One University Plaza, Suite 307, Hackensack, New Jersey 07601
    HOW TO REQUEST PAPER COPIES OF OUR MATERIALS
    PHONE:
    CALL TOLL FREE 1-866-752-8683
    FAX:
    SEND THIS CARD TO 202-521-3464
    INTERNET: https://www.iproxydirect.com/CSBR AND FOLLOW ON-SCREEN INSTRUCTIONS
    EMAIL:
    [email protected] INCLUDE YOUR CONTROL ID IN YOUR EMAIL
    This communication represents a notice to access a more complete set of proxy materials available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The proxy statement is available at: https://www.iproxydirect.com/CSBR
    If you want to receive a paper copy of the proxy materials you must request one. There is no charge to you for requesting a copy. To facilitate timely delivery please make the request, as instructed above, before September 30, 2024
    you may enter your voting instructions at https://www.iproxydirect.com/CSBR
    until 11:59 pm eastern time October 13, 2024.
    The purposes of this meeting are as follows:
    1.Elect the seven Board of Director nominees named in the accompanying Proxy Statement to the Board of Directors for the ensuing year and until his successor has been elected and qualified, or until his earlier death, resignation or removal;
    2.Ratify the appointment of EisnerAmper LLP as our independent registered public accounting firm for the fiscal year ending April 30, 2025;
    3.Approve a non-binding advisory resolution relating to the compensation of our named executive officers; and
    4.Transact such other business as may properly come before the meeting or any adjournments or postponements thereof.
    Pursuant to Securities and Exchange Commission rules, you are receiving this Notice that the proxy materials for the Annual Meeting are available on the Internet. Follow the instructions above to view the materials and vote or request printed copies.
    The board of directors has fixed the close of business on August 26, 2024 as the record date for the determination of stockholders entitled to receive notice of the Annual Meeting and to vote the shares of our common stock, par value $.001 per share, they held on that date at the meeting or any postponement or adjournment of the meeting.
    The Board of Directors recommends that you vote ‘for’ all proposals above.
    Please note - This is not a Proxy Card - you cannot vote by returning this card




    Champions Oncology, Inc.
    SHAREHOLDER SERVICES
    1 Glenwood Avenue Suite 1001
    Raleigh NC 27603





    Time Sensitive shareholder information enclosed















    IMPORTANT SHAREHOLDER INFORMATION

    YOUR VOTE IS IMPORTANT
    Get the next $CSBR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CSBR

    DatePrice TargetRatingAnalyst
    9/12/2024$6.00Hold → Buy
    Craig Hallum
    More analyst ratings

    $CSBR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership

      HACKENSACK, NJ / ACCESSWIRE / January 8, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with specialty testing services, is excited to announce significant advancements in its bioanalytical services portfolio, specifically, expanding its capabilities with the integration of multiple global Cytek Aurora flow cytometers and the appointment of Troy Tremaine, MBA, to spearhead Bioanalytical Commercial Strategy.The addition of Cytek Aurora instruments elevates Champions' service offerings, building on its already competitive spectral and conventional flow cytometry capabilities. The continued investment in this clinical portfolio of serv

      1/8/25 8:00:00 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million

      HACKENSACK, NJ / ACCESSWIRE / December 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2025, ended October 31, 2024.Second Quarter and Recent Highlights:Total revenue increased 17% to $13.5 millionGross profit of $6.1 million; margin of 45%Net income of approximately $730,000Adjusted EBITDA of $1.1 millionDevelopment of new data revenue streamFirst Half 2025 Highlights:Total revenue increased 14% to $27.6 millionGross profit of $13.1 million; margin of 47%Net income of $2.1 millionAdjusted EBITDA of $3.2 millionRonni

      12/11/24 4:00:00 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024

      HACKENSACK, NJ / ACCESSWIRE / December 5, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31, 2024, on Wednesday, December 11, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 710610. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 51750, or

      12/5/24 4:30:00 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CSBR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Champions Oncology Inc.

      SC 13G/A - CHAMPIONS ONCOLOGY, INC. (0000771856) (Subject)

      11/14/24 9:53:10 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Champions Oncology Inc. (Amendment)

      SC 13D/A - CHAMPIONS ONCOLOGY, INC. (0000771856) (Subject)

      5/6/24 7:46:06 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Champions Oncology Inc.

      SC 13G - CHAMPIONS ONCOLOGY, INC. (0000771856) (Subject)

      2/12/24 9:12:00 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CSBR
    Leadership Updates

    Live Leadership Updates

    See more
    • Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership

      HACKENSACK, NJ / ACCESSWIRE / January 8, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with specialty testing services, is excited to announce significant advancements in its bioanalytical services portfolio, specifically, expanding its capabilities with the integration of multiple global Cytek Aurora flow cytometers and the appointment of Troy Tremaine, MBA, to spearhead Bioanalytical Commercial Strategy.The addition of Cytek Aurora instruments elevates Champions' service offerings, building on its already competitive spectral and conventional flow cytometry capabilities. The continued investment in this clinical portfolio of serv

      1/8/25 8:00:00 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology Announces the Addition of Brady Davis as President

      HACKENSACK, NJ / ACCESSWIRE / October 17, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, has appointed Brady Davis as President to continue to develop new strategic initiatives to drive accelerated growth."We are thrilled to have Brady join the already incredibly talented team here at Champions Oncology. Brady has deep healthcare, data and oncology-specific experience and has a proven track record of building products and solutions that align with customer needs," stated Ronnie Morris, CEO of Champions Oncology.Mr. Davis brings more than 25 years of international experience leading medical

      10/17/23 8:30:00 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology Announces Addition to Board of Directors

      HACKENSACK, NJ / ACCESSWIRE / February 22, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR) a leading global oncology technology solutions provider transforming drug discovery through innovative pharmacology, biomarker, and data platforms, is pleased to announce the appointment of Rob Brainin to its Board of Directors. Rob is an experienced global life sciences and healthcare executive with more than 15 years of experience. His appointment will help guide the company's efforts to accelerate the development of its data platform for use in drug discovery. The Company also announced the resignation of current board member Abba Poliakoff. Joel Ackerman, Chairman of the Board of Directors commented

      2/22/21 9:00:00 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CSBR
    Financials

    Live finance-specific insights

    See more
    • Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million

      HACKENSACK, NJ / ACCESSWIRE / December 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2025, ended October 31, 2024.Second Quarter and Recent Highlights:Total revenue increased 17% to $13.5 millionGross profit of $6.1 million; margin of 45%Net income of approximately $730,000Adjusted EBITDA of $1.1 millionDevelopment of new data revenue streamFirst Half 2025 Highlights:Total revenue increased 14% to $27.6 millionGross profit of $13.1 million; margin of 47%Net income of $2.1 millionAdjusted EBITDA of $3.2 millionRonni

      12/11/24 4:00:00 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024

      HACKENSACK, NJ / ACCESSWIRE / December 5, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31, 2024, on Wednesday, December 11, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 710610. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 51750, or

      12/5/24 4:30:00 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million

      HACKSENSACK, NJ / ACCESSWIRE / September 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its first quarter of fiscal 2025, ended July 31, 2024.First Quarter Highlights:Total revenue increased 12% to $14.1 millionMargin improved to 50%Adjusted EBITDA of $2.0 millionNet income of $1.3 millionRonnie Morris, CEO of Champions, commented, "As outlined on our year-end earnings call, we're cautiously optimistic that we've weathered the worst of the business downturn and we're poised to emerge leaner and stronger. Our first quarter's performance provided

      9/11/24 4:00:00 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CSBR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Breitfeld Philip P. disposed of 4,150 shares, decreasing direct ownership by 42% to 5,717 units (SEC Form 4)

      4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

      4/2/25 4:20:36 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Breitfeld Philip P.

      4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

      11/18/24 12:14:09 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Sidransky David

      4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

      11/18/24 11:47:41 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CSBR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mendelson Daniel Newman bought $6,500 worth of shares (1,000 units at $6.50), increasing direct ownership by 0.51% to 198,625 units (SEC Form 4)

      4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

      1/16/24 11:45:44 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mendelson Daniel Newman bought $12,540 worth of shares (2,000 units at $6.27), increasing direct ownership by 1% to 197,625 units (SEC Form 4)

      4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

      1/12/24 12:47:07 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mendelson Daniel Newman bought $18,577 worth of shares (2,944 units at $6.31), increasing direct ownership by 2% to 195,625 units (SEC Form 4)

      4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

      1/11/24 10:57:35 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CSBR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Champions Oncology upgraded by Craig Hallum with a new price target

      Craig Hallum upgraded Champions Oncology from Hold to Buy and set a new price target of $6.00

      9/12/24 9:23:16 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Roth Capital reiterated coverage on Champions Oncology with a new price target

      Roth Capital reiterated coverage of Champions Oncology with a rating of Buy and set a new price target of $16.00 from $13.50 previously

      3/15/21 10:03:32 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CSBR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Champions Oncology Inc.

      10-Q - CHAMPIONS ONCOLOGY, INC. (0000771856) (Filer)

      3/17/25 11:03:52 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CHAMPIONS ONCOLOGY, INC. (0000771856) (Filer)

      3/11/25 4:32:41 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Champions Oncology Inc.

      10-Q - CHAMPIONS ONCOLOGY, INC. (0000771856) (Filer)

      12/16/24 4:16:03 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care